Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD)

被引:28
|
作者
Morrison, CE
Borod, JC
Brin, MF
Hälbig, TD
Olanow, CW
机构
[1] NYU, Med Ctr, Comprehens Epilepsy Ctr, New York, NY 10016 USA
[2] Mt Sinai Sch Med, Dept Neurol, New York, NY USA
[3] CUNY Queens Coll, Dept Psychol, New York, NY USA
[4] CUNY, Grad Ctr, New York, NY USA
[5] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA
[6] Allergan LLC, Irvine, CA USA
关键词
Parkinson's disease; levodopa; cognitive; depression;
D O I
10.1007/s00702-004-0145-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although improved cognition has been reported in patients with mild Parkinson's disease (PD) following the administration of levodopa, mixed results have been found in moderately-to-severely affected PD patients (MSPD), particularly in studies conducted since 1980. In the present study, 16 MSPD patients were tested on separate days, once following overnight levodopa withdrawal and once while optimally treated. A battery of neuropsychological tests that assess a range of cognitive functions (i.e., attention, language, visuospatial, memory, and executive), as well as a measure of depression, were used. Although patients performed better on a measure of confrontation naming in the untreated than in the treated condition, there were no significant differences for any of the other cognitive variables or for the depression scale variable. Thus, these data suggest that there are generally no adverse or beneficial effects of levodopa therapy on cognition in MSPD patients.
引用
收藏
页码:1333 / 1341
页数:9
相关论文
共 50 条
  • [1] Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD)
    C. E. Morrison
    J. C. Borod
    M. F. Brin
    T. D. Hälbig
    C. W. Olanow
    Journal of Neural Transmission, 2004, 111 : 1333 - 1341
  • [2] Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease
    Burke, David
    ANNALS OF INTERNAL MEDICINE, 2012, 156 (12) : JC6 - JC10
  • [3] Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease
    Funkiewiez, Aurelie
    Ardouin, Claire
    Cools, Roshan
    Krack, Paul
    Fraix, Valrie
    Bair, Alina
    Chabardes, Stephan
    Benabid, Alim-Louis
    Robbins, Trevor W.
    Pollak, Pierre
    MOVEMENT DISORDERS, 2006, 21 (10) : 1656 - 1662
  • [4] Effects of levodopa on cognitive functions in Parkinson's disease
    Ismailova, S.
    Prokopenko, S.
    MOVEMENT DISORDERS, 2021, 36 : S293 - S293
  • [5] Efficacy and safety of preladenant, a novel A2A receptor antagonist, as a levodopa adjunct in patients with moderate-to-severe Parkinson's disease
    Hauser, R. A.
    Pourcher, E.
    Micheli, F.
    Mok, V.
    Onofrj, M.
    Huyck, S. B.
    Wolski, K. P.
    Cantillon, M.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S116 - S116
  • [6] Effects of depression and Parkinson's disease on cognitive functioning
    Norman, S
    Tröster, AI
    Fields, JA
    Brooks, R
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2002, 14 (01) : 31 - 36
  • [7] Cognitive and emotional factors influence specific domains of postural control in individuals with moderate-to-severe Parkinson's disease
    de Oliveira, Claudia Eunice Neves
    Coelho, Daniel Boari
    de Souza, Caroline Ribeiro
    Batista, Alana Xavier
    Marquesini, Raquel
    Moreira-Neto, Acacio
    Silva-Batista, Carla
    Bitiati, Adriana Tanigawa
    Teixeira, Luis Augusto
    de Lima-Pardini, Andrea Cristina
    GAIT & POSTURE, 2023, 101 : 66 - 72
  • [8] Assessment of Visual Field in Patients with Moderate-to-Severe Parkinson's disease (PD)
    Mehta, S.
    Syed, M.
    Naghizadehkashani, S.
    Shivok, K.
    Krisa, L.
    Matias, C.
    Wu, C.
    Liang, T.
    Sergott, R.
    Alizadeh, M.
    MOVEMENT DISORDERS, 2024, 39 : S500 - S501
  • [9] Levodopa and cognitive disorders in Parkinson's disease
    Leiva-Santana, C.
    Alvarez-Sauco, M.
    REVISTA DE NEUROLOGIA, 2006, 43 (02) : 95 - 100
  • [10] Intrinsic Auricular Muscle Zone Stimulation for Moderate-to-Severe Parkinson's disease (PD)
    Brillman, S.
    Samiian, A.
    Sharma, V.
    Ertan, S.
    Cakmak, O.
    MOVEMENT DISORDERS, 2024, 39 : S313 - S313